Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 5, 2004, Pages 415-420

  Jang, Jeong Won ^a   Park, Young Min ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a   Chang, U Im ^a   Nam, Soon Woo ^a   Kim, Boo Sung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Combination therapy; ECF regimen; Hepatocellular carcinoma; Percutaneous ethanol injection

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GELFOAM;

ABDOMINAL PAIN; ADULT; ARTICLE; ASCITES; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEPATITIS; HUMAN; INFUSION; INTERMETHOD COMPARISON; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PAIN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME;

ADMINISTRATION, CUTANEOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; EPIRUBICIN; ETHANOL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 7744235182     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0829-7     Document Type: Article

References (14)

1. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL (2002) Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50:305-308
2. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ (2000) Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88:1986-1991
3. Etienne MC, Bernard S, Fischel JL, Formento P, Gioanni J, Santini J, Demard F, Schneider M, Milano G (1991) Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 63:372-377
4. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261
5. Levy AE, Kowdley KV (2001) Unresectable hepatocellular carcinoma: the need for an individualized multidisciplinary approach. J Clin Gastroenterol 33:180-182
6. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J; Barcelona Liver Cancer Group (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739
7. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171
8. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181-184
9. Suzuki M, Suzuki H, Yamamoto T, Mamada Y, Mizuno H, Tominaga T, Suga M, Suemori S, Kato Y, Sato A, Yamanouchi E, Sakuyama K, Maeyama S, Shinagawa T, Okabe K (1997) Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma. Semin Oncol 24:S6-110-115
10. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S (1987) Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 163:345-351
11. Teo EK, Fock KM (2001) Hepatocellular carcinoma: an Asian perspective. Dig Dis 19:263-268
12. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F (2000) Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 32:233-238
13. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269-272
14. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underbill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267